Percutaneous Coronary Intervention

Ticagrelor (Brilinta, AstraZeneca) vs. clopidogrel as a preloading treatment in high-risk nonemergent PCI.

Healio’s live coverage of the virtual American Heart Association Scientific Sessions dominated the top stories in cardiology for the second week in a row.

Prognostic value and therapeutic potential of flow and pressure measurements to assess coronary artery stenosis.

Safety and efficacy of prehospital administration of crushed prasugrel (Effient, Daiichi Sankyo/Eli Lilly) vs. uncrushed tablets in patients with STEMI.

Cannabis use in the U.S. is rising, and although users are typically younger, their risk for acute MI is elevated, and after PCI, cannabis users may be at increased risk for bleeding and stroke compared with nonusers, researchers reported.

A novel healing-targeted drug-eluting stent was as safe and effective as a standard durable polymer DES among adults with acute and chronic coronary disease undergoing PCI, early data from the PIONEER III trial show.

In a single-center analysis, cardiac catheterization procedures decreased during a 6-week period of the COVID-19 lockdown compared with the same span in 2019, researchers reported.

One month of dual antiplatelet therapy followed by aspirin monotherapy after PCI with a polymer-free drug-coated stent was noninferior to 6 to 12 months of DAPT after PCI with a contemporary drug-eluting stent, researchers reported.

Ticagrelor was not superior to clopidogrel for reducing periprocedural myocardial necrosis or myocardial injury within 48 hours of high-risk elective PCI performed in patients with stable coronary disease, according to the ALPHEUS trial.

Among patients with stable ischemic heart disease enrolled in the ISCHEMIA trial, those with chronic total occlusion lesions had similar outcomes compared with those who did not.